FDA
-
-
-
-
-
-
-
Insys Therapeutics (INSY) Reports Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis
-
-
-
-
-
-
-
Insys Therapeutics (INSY) Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus IM and IV Naloxone for Opioid Overdose
-
-
-
-
-
-
-
INSYS Therapeutics Reports Second Quarter 2018 Results
-
-
-
-
-
-
-
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
-
-
-
-
-
-
-
Insys Therapeutics (INSY) Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
-
-
-
-
-
-
-
Pre-Open Movers 12/26: (DMPI) (APTO) (INSY) Higher; (SWKS) (AAPL) (CRUS) Lower (more...)
-
-
-
-
-
-
-
New Jersey AG Porrino Announces Lawsuit Alleging Scheme to Boost Sales by Fentanyl Drug Maker Insys (INSY)
-
322,224 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

